This article is a correction to:
The Increased Risk of Thyroid Cancer-Specific Mortality With Tumor Size in Stage IVB Patients
Xiaojuan Zha1,2†Zhenchun Miao1,2†Xiu Huang2†
Xingchun Wang1,2Ruting Xie3Jiaoying Jin3Dajin Zou1,2Peng Yang1,2
Yueye Huang1,2*- 1Shanghai Center of Thyroid Diseases, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
- 2Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
- 3Department of Pathology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
By Zha X, Miao Z, Huang X, Wang X, Xie R, Jin J, Zou D, Yang P and Huang Y (2022). Front. Endocrinol. 13:822423. doi: 10.3389/fendo.2022.822423
In the originally published article, there were errors each of the author affiliations.
Affiliation 1 should have been presented as “Shanghai Center of Thyroid Diseases, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China”, and not as “Shanghai Center of Thyroid Diseases, Shanghai, China”.
Affiliation 2 should have been presented as “Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China”, and not as “Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China”
Affiliation 3 should have been presented as “Department of Pathology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China”, and not as Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China”.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Bethesda category III, papillary thyroid cancer, fine‐needle aspiration, extra-thyroid extension, active surveillance
Citation: Zha X, Miao Z, Huang X, Wang X, Xie R, Jin J, Zou D, Yang P and Huang Y (2022) Corrigendum: The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine‐Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment. Front. Endocrinol. 13:911963. doi: 10.3389/fendo.2022.911963
Received: 03 April 2022; Accepted: 11 April 2022;
Published: 18 May 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Zha, Miao, Huang, Wang, Xie, Jin, Zou, Yang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yueye Huang, huangyueye19890603@163.com
†These authors have contributed equally to this work